Network pharmacology and in vitro studies reveal the pharmacological effects and molecular mechanisms of Shenzhi Jiannao prescription against vascular dementia

Danfeng Tian1†, Qiang Gao1†, Ze Chang1, Jingfeng Lin1, Dayong Ma2 and Zhenyun Han3**

Abstract

Background: Shenzhi Jiannao (SZJN) prescription is a type of herbal formula adopted in the management of cognitive impairment and related disorders. However, its effects and related regulatory mechanisms on vascular dementia (VD) are elusive. Herein, network pharmacology prediction was employed to explore the pharmacological effects and molecular mechanisms of SZJN prescription on VD using network pharmacology prediction, and validated the results through in vitro experiments.

Methods: Through a search in the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database, chemical composition and targets for SZJN prescription were retrieved. The potential targets for VD were then obtained from the GeneCards and DisGeNET databases. The network was constructed that depicted the interactions between putative SZJN prescription and known therapeutic targets for VD using Cytoscape 3.7.1. Analysis of protein-protein interaction was achieved via STRING 11.0 software, followed by Gene Ontology (GO) functional enrichment and Kyoto Gene and Genome Encyclopedia (KEGG) pathway analyses. To validate the computer-predicted results, in vitro experiments based on an excitotoxic injury model were designed using glutamate-exposed PC12 cells, and treated with varying concentrations (low, 0.05; medium, 0.1 and high, 0.2 mg/mL) of SZJN prescription. Cell viability and cell death were detected using the IncuCyte imaging system. Moreover, the expression profiles of Caspase-3 were analyzed through qRT-PCR.

Results: Twenty-eight potentially active ingredients for SZJN prescription, including stigmasterol, beta-sitosterol, and kaempferol, plus 21 therapeutic targets for VD, including PTGS2, PTGS1, and PGR were revealed. The protein-protein interaction network was employed for the analysis of 20 target proteins, including CASP3, JUN, and AChE. The enrichment analysis demonstrated candidate targets of SZJN prescription were more frequently involved in neuroactive ligand-receptor interaction, calcium, apoptosis, and cholinergic synaptic signaling pathways. In vitro experiments revealed that SZJN prescription could significantly reverse glutamate-induced cell viability loss and cell death, and lower the levels of Caspase-3 mRNA in glutamate-induced PC12 cells.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: Collectively, this study demonstrated that SZJN prescription exerted the effect of treating VD by regulating multi-targets and multi-channels with multi-components through the method of network pharmacology. Furthermore, in vitro results confirmed that SZJN prescription attenuated glutamate-induced neurotoxicity.

Keywords: Shenzhi Jiannao prescription, Network pharmacology, Vascular dementia, Pharmacological effects and molecular mechanisms, In vitro studies

Background
Vascular dementia (VD), as the main type of dementia in Asia, is mainly the result of vascular risk factors such as atherosclerosis, hypertension and micro-strokes [1]. VD accounts for about 30% of dementia in Asia, and the incidence rate in China is 1.1 to 3% [2–4]. With aging, the incidence of VD is doubled every 5.3 years, which brings about a large burden on society and patients’ families [2, 5]. The currently used primary preventive medications, including cholinesterase inhibitors and excitatory amino acid receptor antagonists against vascular cognitive impairment have very limited efficacy. Thus far, there are no curative treatments available and therefore, development of therapy for VD has become an essential but unmet need. A large number of experimental studies and clinical observations have confirmed that Chinese medicine has unique advantages in treating VD. Various empirical prescriptions and active ingredient extracts have shown clear neuroprotective effects on VD [6–8].

Shenzhi Jiannao (SZJN) prescription, the national new formula in China (ZL201010249665.8), is a classical herbal formula for the treatment of VD based on the clinical practice. This prescription is mainly composed of Panax ginseng C.A. Mey. (Ginseng), Anemarrhena asphodeloides Bunge (Anemarrhenae), and Paeonia veitchii Lynch (Paeoniae rubra). In previous pharmacological study, it has been found that SZJN prescription improved cerebral ischemia in VD rats, reduced the levels of glutamate and γ -aminobutyric acid in the anterior cortex, and increased acetylcholine content [9]. Moreover, SZJN prescription was associated with significantly low expression of N-methyl-D-aspartate receptor 1 (NMDAR1) in the brain of rats with vascular dementia. Furthermore, administration of this prescription impeded the loss of hippocampal neurons, neuronal damage, degeneration, and necrosis; this consequently improved cognitive function [10, 11]. The effect of SZJN prescription on the central cholinergic system improves the cognitive ability of mice with acquired memory disorder through inhibition of AChE activity [12]. However, reports about the therapeutic effects and mechanisms of action of SZJN prescription on VD are scanty. The molecular mechanism of SZJN prescription has not been certainly clear.

Network pharmacology approaches have been proven to be a powerful way for mechanistic exploration of Chinese medicine from the perspective of multicomponents, multitargets, and multichannels, which is consistent with the holistic view of Chinese medicine [13, 14]. The aim of this study was to explore the underlying molecular mechanisms of SZJN prescription in treating vascular dementia by using network pharmacology approaches and its protective effect on glutamate-induced neurotoxicity by in vitro experiment based on network pharmacology prediction. These findings provide a new scientific basis for the future development of SZJN prescription. A flowchart of the experimental procedures of this study is outlined in Fig. 1.

Methods
Collection, retrieval, and screening of main chemical components of SZJN prescription
To determine and collect the chemical components of the three herbs contained in SZJN prescription, a search was performed from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database (TCMSP, http://ibts.hkbu.edu.hk/lsp/tcmsp.php) manually. Subsequently, compound names and their molecular structures were verified in the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Oral bioavailability (OB) ≥ 30% and drug-like (DL) ≥ 0.18 parameters were incorporated in the TCMSP database as drug screening conditions for the compounds.

Predicting SZJN prescription chemical components targets, VD significant targets and SZJN prescription therapeutic targets
The main chemical components in SZJN prescription were determined and individually matched with potential targets according to TCMSP. First, names of the predicted target proteins were transformed into gene names via the UniProt database (http://www.uniprot.org/), then target species were selected as “humans”. Targets related to VD were collected from two databases. One was the GeneCards (https://www.genecards.org/), which is a searchable, integrative database that provides comprehensive, user-friendly information on all annotated and predicted human genes [15]. The other database was the DisGeNET (http://www.disgenet.org/), which is a comprehensive gene-disease association (GDA) database that provides the current knowledge of human
genetic diseases [16]. A general search for all genes was conducted using the keywords "vascular dementia," then retrieved from the GeneCards and DisGeNET databases. An intersection between SZJN prescription targets and VD significant targets was made to obtain the therapeutic targets for SZJN prescription for subsequent studies.

**Network construction and analysis**

Using the Cytoscape 3.7.1 software, prediction results of potential targets for SZJN prescription were acquired, and a network of herbs-putative active components-putative therapeutic targets was constructed. The network topology analysis was achieved using a plugin in Cytoscape 3.7.1, after which a protein-protein interaction (PPI) network of the SZJN prescription was constructed via the STRING 10.5 (https://string-db.org) software.

**Analysis of Gene Ontology (GO) function enrichment and Kyoto Genes and Genomes Encyclopedia (KEGG) pathway enrichment**

GO functional enrichment and KEGG pathway enrichment analyses were conducted using the David v 6.8 database (https://david.ncifcrf.gov/) to explore gene functions and uncover potential therapeutic targets of the active components of SZJN prescription. Analysis of the pathways provided scientific connotation for SZJN prescription.
Materials and reagents for biological experiments
Differentiated PC12 cells, RPMI-1640 complete culture medium (containing 10% FBS, 100 U/mL penicillin, and 100 U/mL of streptomycin) and RPMI-1640 basic culture medium were purchased from Procell Life Science and Technology Co. Ltd. (Wuhan, China); Caspase-3 primers were synthesized by Sangon Biotechnology Co. Ltd. (Shanghai, China); L-glutamic acid (glutamate) was purchased from Sigma (USA); SZJN prescription, constituted from Ginseng, Anemarrhena, and Paeoniae rubra, was acquired from the Chinese Medicine Preparation Department of China-Japan Friendship Hospital; Memantine hydrochloride (MH) was purchased from H. Lundbeck A/S (Denmark). SZJN prescription and glutamate were dissolved in RPMI 1640 complete medium, while MH was dissolved in dimethyl sulfoxide (DMSO) to obtain a final concentration of less than 0.5% for use in the experiments.

Cell culture and modeling intervention
PC12 cells were cultured in RPMI-1640 complete medium at 95% humidity, 5% carbon dioxide (CO₂), and a temperature of 37°C. Cells were treated with or without SZJN prescription (0.05, 0.1 and 0.2 mg/mL), MH (10 μM), and glutamate (22.5 mM) for 24 h. Each experiment was performed in triplicate.

Cell viability and cell death assays
Real-time examination of cell viability and cell death was achieved using the live-cell Essen Bioscience IncuCyte imaging system, which recorded both phase-contrast and fluorescent images over time. Briefly, cells (30,000 cells/well) were seeded into Corning 96-well tissue culture plates and then placed on the IncuCyte instrument. For cell viability and cell death were recorded for over 36 h. Dead cells were identified using fluorescent nuclear dye YOYO-1 (Thermo Fisher Scientific, USA), a cell impermeable dye that enters cells via compromised membranes. To calculate the average percentage of cell death, the green fluorescent area (YOYO-1 positive) was divided by the total phase area.

Cell apoptosis using flow cytometry (FCM)
Apoptotic cells were quantitated using the Annexin V-FITC/propidium iodide (PI) apoptosis assay kit (Key-GEN BioTECH, China). Briefly, PC12 cells were digested with 0.25% trypsin, centrifuged, and resuspended in 200 μL 1× binding buffer. Then, cells were stained with 5μL Annexin V-FITC in the dark for 10 min. This was followed by another staining with 5μL PI for 5 min. Samples were analyzed using a FACScan flow cytometer (BD, USA). At least 10,000 events were recorded. Apoptotic cells were expressed as a percentage of the total number of cells.

Effect of SZJN prescription on the mRNA expression of Caspase-3 in glutamate-treated PC12 cells
The effect of SZJN prescription on Caspase-3 was established through quantitative real-time polymerase chain reaction (qRT-PCR) analysis. Briefly, total RNA from cells was extracted using the RNA Extraction Kit (KURABO, Japan) according to the manufacturer’s instructions. The concentration and purity of the extracted RNA were determined using a Q5000 nucleic acid protein analyzer (Quawell, USA). Then a reverse transcription kit (Thermo Fisher Scientific, USA) was used to reverse transcribed the RNA to cDNA. qRT-PCR was performed using the SYBR Green Master Mix on a CFX Connect Real-Time PCR System (Bio-Rad, USA), with Caspase-3: Forward: 5′-GTACAGAGCTGGACTCGGTATTG-3′; Reverse: 5′-AGTCGGCTCCACTGGATCCTTC-3′ and β-actin: Forward: 5′-GCAGTGGATTGAGCAAG-3′; Reverse: 5′-ATGCCGTTGACTTGGAG-3′ primer pairs. qRT-PCR conditions were as follows: Initial denaturation step at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, 60°C for 1 min. β-actin served as the internal reference gene. The relative expression levels of target genes were calculated using the 2^-∆∆CT method.

Statistical analysis
All statistical analyses were performed via SPSS version 25.0. Data were presented as means ± standard deviations (SD). Statistical comparisons were achieved using one-way analysis of variance (ANOVA) for multiple groups with variance depicting homogeneous normal distribution data. Least—Significant Difference (LSD) test was applied for mean separations to reveal statistically significant differences, P<0.05.

Results
Potential active components of SZJN prescription
Based on the set conditions in the database, 45 potentially active SZJN prescription components were retrieved and screened, including 17, 15, and 13 for Ginseng, Anemarrhena, and Paeoniae rubra, respectively (Table 1).

Predicted targets for SZJN prescription chemical components, VD significant and therapeutic targets
Names of component targets in SZJN prescription were corrected using the UniProt database, after which repeated targets were eliminated. Eventually, 61, 90, and 71 potential targets for Ginseng, Anemarrhena, and Paeoniae rubra respectively, were obtained, respectively. From the GeneCards and DisGeNET databases
| Herb              | Mol ID      | Molecule Name                                      | MW   | OB (%) | DL  |
|------------------|-------------|----------------------------------------------------|------|--------|-----|
| Ginseng          | MOL005348   | Ginsenoside-Rh4_qt                                 | 458.8| 31.11  | 0.78|
| Ginseng          | MOL005357   | Schisantherin B                                    | 514.62| 31.99  | 0.83|
| Ginseng          | MOL005376   | Panaxadiol                                         | 460.82| 33.09  | 0.79|
| Ginseng          | MOL005344   | Ginsenoside Rh2                                    | 622.98| 36.32  | 0.56|
| Ginseng          | MOL000358   | beta-Sitosterol                                    | 414.79| 36.91  | 0.75|
| Ginseng          | MOL005399   | alexandrin_qt                                      | 414.79| 36.91  | 0.75|
| Ginseng          | MOL004492   | Chrysanthemaxanthin                                | 584.96| 38.72  | 0.58|
| Ginseng          | MOL005317   | Depoxyharringtonine                                | 515.66| 39.27  | 0.81|
| Ginseng          | MOL005401   | Ginsenoside Rg5_qt                                 | 442.8 | 39.56  | 0.79|
| Ginseng          | MOL002879   | Diisooctyl phthalate                               | 390.62| 43.59  | 0.39|
| Ginseng          | MOL000449   | Stigmasterol                                       | 412.77| 43.83  | 0.76|
| Ginseng          | MOL005384   | Suchilactone                                       | 368.41| 57.52  | 0.56|
| Ginseng          | MOL005360   | Malkangunin                                        | 432.56| 57.71  | 0.63|
| Ginseng          | MOL000787   | Protopine                                          | 353.4 | 59.26  | 0.83|
| Ginseng          | MOL003648   | (+)-Maackiain                                      | 284.28| 65.83  | 0.54|
| Ginseng          | MOL005321   | Frutinone A                                        | 264.24| 65.9   | 0.34|
| Ginseng          | MOL005314   | Celabenzine                                        | 379.55| 101.88 | 0.49|
| Anemarrhenae     | MOL001677   | Aurantiamide acetate                               | 444.57| 58.02  | 0.52|
| Anemarrhenae     | MOL003773   | Mangiferolic acid                                  | 442.75| 36.16  | 0.84|
| Anemarrhenae     | MOL000422   | Kaempferol                                         | 286.25| 41.88  | 0.24|
| Anemarrhenae     | MOL004373   | Icaritin                                           | 368.41| 45.41  | 0.44|
| Anemarrhenae     | MOL004489   | Anemarsaponin F_qt                                 | 432.71| 60.06  | 0.79|
| Anemarrhenae     | MOL004492   | Chrysanthemaxanthin                                | 584.96| 38.72  | 0.58|
| Anemarrhenae     | MOL004497   | Hippeastrine                                       | 315.35| 51.65  | 0.62|
| Anemarrhenae     | MOL004514   | Timosaponin B III_qt                               | 416.71| 35.26  | 0.87|
| Anemarrhenae     | MOL000449   | Stigmasterol                                       | 412.77| 43.83  | 0.76|
| Anemarrhenae     | MOL004528   | Icarin                                             | 676.73| 41.58  | 0.75|
| Anemarrhenae     | MOL004540   | Anemarsaponin C_qt                                 | 416.71| 35.5   | 0.87|
| Anemarrhenae     | MOL004542   | Anemarsaponin E_qt                                 | 448.76| 30.67  | 0.86|
| Anemarrhenae     | MOL000483   | N-cis-Feruloyltyramine                             | 313.38| 118.35 | 0.26|
| Anemarrhenae     | MOL000546   | Diosgenin                                          | 414.69| 80.88  | 0.81|
| Anemarrhenae     | MOL000631   | cis-N-p-Coumaroyltyramine                          | 283.35| 112.9  | 0.2  |
| Paeoniae rubra   | MOL001910   | 11alpha,12alpha-Epoxy-3beta,23-dihydroxy-30-norolean-20(29)-en-28,13beta-olide | 470.71| 64.77  | 0.38|
| Paeoniae rubra   | MOL001918   | Paeoniflorgenone                                   | 318.35| 87.59  | 0.37|
| Paeoniae rubra   | MOL001919   | Palbinone                                          | 358.52| 43.56  | 0.53|
| Paeoniae rubra   | MOL001921   | Lactiflorin                                       | 462.49| 49.12  | 0.8  |
| Paeoniae rubra   | MOL001924   | Paeoniflorin                                      | 480.51| 53.87  | 0.79|
| Paeoniae rubra   | MOL001925   | Paeoniflorin_qt                                   | 318.35| 68.18  | 0.4  |
| Paeoniae rubra   | MOL001928   | Albliflorin_qt                                     | 318.35| 66.64  | 0.33|
| Paeoniae rubra   | MOL001930   | Benzoylpaeoniflorin                               | 584.62| 31.27  | 0.75|
| Paeoniae rubra   | MOL000211   | Betulonic acid                                    | 456.78| 55.38  | 0.78|
| Paeoniae rubra   | MOL000358   | beta-Sitosterol                                    | 414.79| 36.91  | 0.75|
| Paeoniae rubra   | MOL000359   | Sitosterol                                         | 414.79| 36.91  | 0.75|
| Paeoniae rubra   | MOL000422   | Kaempferol                                         | 286.25| 41.88  | 0.24|
| Paeoniae rubra   | MOL000492   | (+)-Catechin                                       | 290.29| 58.43  | 0.24|
successfully revealed all genes related to VD were revealed; 3077 target genes were retrieved. Integrating potential targets of chemically active components in SZJN prescription with those of VD revealed exactly 21 therapeutic targets (Fig. 2).

**Network construction and analysis**

A network of SZJN prescription-active compounds-VD targets was successfully constructed via Cytoscape 3.7.1 for topological analysis (Fig. 3). It comprised 52 nodes and 183 edges; a dark blue node represented single herb (3), a red node depicted active compounds (28), and a light blue node denoted therapeutic targets (21).

Twenty-one therapeutic SZJN prescription targets were input into the STRING software and identified 20 target proteins under the set conditions. These results were saved as a TSV file. Network topology analysis and calculations were performed via Cytoscape 3.7.1, for the construction of a PPI network (Fig. 4a). Based on the degree of the nodes, a bar graph depicting the relationship between all protein nodes and the targets was generated (Fig. 4b).

**GO and KEGG pathway enrichment analyses**

Through GO enrichment analysis of the 20 target proteins in the PPI network, 106 GO items were revealed ($P<0.05$), including 70 items related to biological processes, such as drug reaction, transcription initiation of RNA polymerase II promoter, and steroid mediated signaling pathway; 15 items related to cell composition, such as nuclear and plasma membrane components, and membrane raft; 21 items related to molecular function, (steroid receptor, sequence-specific DNA binding, and enzyme binding) were identified (Fig. 5a-c).

Also, KEGG pathway analysis of the 20 target proteins in the PPI network was performed (at $P<0.05$), and the unrelated pathways including those for cancer and hepatitis B were eliminated. Results demonstrated that the targets of SZJN prescription for treating VD treatment were mainly associated with neuroactive ligand-receptor interaction, calcium, cholinergic synapse, cardiac myocyte adrenergic signal transduction, adipocyte lipolysis regulatory, apoptosis, cAMP, salivary secretion, tumor necrosis factor, 5-hydroxy color Aminergic synaptic, neurotrophin and AMPK signaling pathways (Fig. 6). The SZJN prescription-related targets and pathways associated with apoptosis-mediated VD progression have been
presented in Fig. 7; the pathway targets are marked in white, whereas the targets of SZJN prescription for VD treatment are marked in purple. It was suggested that SZJN prescription potentially regulates apoptosis, therefore, is crucial in VD treatment.

Validation of the neuroprotective effects of SZJN prescription against glutamate-induced PC12 cell death

The results from the network pharmacological analysis demonstrated that cell proliferation, gene transcription, and cell-cell signaling, and apoptosis were associated with multiple synergies of SZJN prescription on VD treatment. The cytotoxicity of glutamate in PC12 cells was evaluated using YOYO-1 and then the neuroprotective effects of SZJN prescription against glutamate-induced cell death were validated. Cells treated with 22.5 mM glutamate exhibited low viability (Fig. 8a) and showed a large total green fluorescence area within 4 h post-treatment (hpt). The fluorescence intensity increased almost 10 times by 36 hpt (Fig. 8b). Similarly, the number of dead cells cultured with glutamate increased by 4 hpt. Death cell counts increased to over 400/image by 24 hpt (Fig. 8c). The average percent cell death recorded every 2 h over 36 h of monitoring for PC12 cells injury is presented in Fig. 8d. Glutamate-induced cells exhibited a significantly high death rate over the time course, approximately 20% after 36 h of treatment. For injured cells, with complete media, less than 5% cell death was reported over the monitoring time. Exposure to glutamate (22.5 mM) triggered cell death, however, this effect was reversed by SZJN prescription (0.05, 0.1, and 0.2 mg/mL). Moreover, SZJN prescription reduced the total green fluorescence, lowered the number of dead cells and the average percentage of cell death, and recovered cell viability (Fig. 8a-d). Microscopic images were analyzed for positive cell nuclei based on the size and fluorescence intensity of YOYO-1. Representative images of YOYO-1 positive cells at 0, 12, 24, 36 hpt are presented in Fig. 8e.

SZJN prescription prevented glutamate-induced PC12 cell death through apoptosis

Annexin V-FITC/PI double staining was employed to examine apoptotic cells and verify the preventive effects of SZJN prescription on glutamate-induced neurotoxicity through inhibition of cell apoptosis (Fig. 9a). In Fig. 9b, 35.23% ± 17.03% of cells treated with glutamate for 24 h were detected in the apoptotic stage and were significantly higher than the control group (8.53% ± 0.21%, P < 0.01). However, SZJN prescription treatment (0.05, 0.1, and 0.2 mg/mL) and MH significantly decreased the number of apoptotic cells to 15.87% ± 6.37%, 16.47% ± 4.13%, 9.47% ± 0.67% and 12.30% ± 1.67%, respectively.
Fig. 4 Topological analysis of the target proteins of VD and SZJN prescription. 

a PPI network diagram of the common targets of VD and SZJN prescription. 

b Bar graph of all protein nodes degree related to the targets.
Fig. 5 Bubble chart showing GO enrichment analyses. a GO-BP enrichment analysis. b GO-CC enrichment analysis. c GO-MF enrichment analysis.
respectively ($P<0.05$). The results demonstrated that SZJN prescription inhibited glutamate-induced apoptosis of PC12 cells.

Expression profiles of Caspase-3 mRNA were detected using qRT-PCR. Notably, the relative levels of Caspase-3 mRNA were significantly higher after treatment with glutamate ($4.05 \pm 0.55$) compared to the control group ($1.00 \pm 0.00$, $P<0.01$). Caspase-3 expression in the SZJN prescription group showed significantly varying profiles as follows: low (SZJN-L, $1.37 \pm 0.33$, $P<0.01$), middle (SZJN-M, $2.13 \pm 0.53$, $P<0.01$) and high (SZJN-H, $2.11 \pm 0.61$, $P<0.01$) relative to the glutamate group. The expression levels in the SZJN-L group exhibited the highest decreasing trend, whereas the expression of Caspase-3 mRNA in the MH group decreased significantly ($1.33 \pm 0.24$, $P<0.01$) (Fig. 9c).

**Discussion**

According to the theory of traditional Chinese medicine (TCM), VD is described as “dementia” or “stroke combined with dementia”. The pathogenesis of VD in TCM is related to “a deficiency of essential Qi with toxin damaging brain collaterals”. Since VD lasts longer, blockage of the Qi and blood may induce cognitive impairment because brain neurons get limited nutrients [17]. Therefore, approaches that improve the essential energy are vital in the treatment of VD. They can also, detoxify and unblock the collaterals. Consequently, the Qi and blood eliminate the accumulated toxigenic products thereby, establishing SZJN prescription.

Previous studies have revealed that several TCM components exert their therapeutic effects by acting on multiple targets [18–21]. For instance, Ginseng was found to improve intelligence and relaxation of the nerves, while ginsenosides have the potential to prevent cerebral ischemia and repair neuron damage, which consequently improves vascular cognitive impairment [22, 23]. Similarly, studies have reported that Anemarrhena-derived saponins improve cerebral ischemia and hypoxia; this subsequently enhances neurotrophic cognitive ability [24, 25]. Additional reports have demonstrated that Paeoniae rubra potentially protects neurons from hypoxia- or neurotoxicity-derived injury, and reduces inflammatory response [26, 27]. A combination of various herbs in SZJN prescription restore blood collaterals by eliminating phlegm, blood stasis, and collateral toxins. Herbal combinations can strengthen the vital energy and tonify the deficiency, detoxify and unblock collaterals, reduce turbidity and benefit
wisdom. In the present study, 28 active compounds in SZJN prescription, 222 compound-related targets, and 3077 VD-related targets were revealed from the public databases. In details, the degree of these three herbs was as follows: Ginseng (12), Anemarrhena (11), and Paeoniae rubra (8), consistent with their compatibility with SZJN prescription. Ginseng is regarded as the sovereign medicine, whereas Anemarrhena and Paeoniae rubra are considered minister and assistant medicines, respectively [28]. Thus, it may be speculated that Ginseng had a promising potential in the treatment of VD.

A total of 28 active compounds after eliminating the duplicates were identified, particularly, stigmasterol, beta-sitosterol (β-sitosterol), and kaempferol exhibited obvious bioactivities. Pharmacological studies have confirmed that stigmasterol, β-sitosterol and kaempferol are active components of Ginseng [29, 30]. Moreover, these compounds have been revealed as chemical components of Anemarrhena and Paeoniae rubra [31, 32]. Stigmasterol can significantly relieve the vascular inflammation and nerve damage through reducing NO levels, COX-2 expression and apoptotic responses [33, 34]. In particular, stigmasterol and β-sitosterol were reported to significantly improve vanadium-induced cognitive ability in mice and were associated with improved motor coordination potential and a reduction in anti-oxygen free radicals and oxidative stress [35]. It has been found that β-sitosterol can lower the cholesterol levels, enhance the production of plasminogen activators, and prevent endothelial dysfunction [36]. β-sitosterol plays a vital role in the direct endothelial protective and antiatherogenic effects against oxidized low-density lipoprotein.

![Fig. 7](image-url) Pathway map of SZJN prescription against VD. The key targets of SZJN prescription in the treatment of VD are shown purple in the apoptosis pathway. Arrows represent the activation effect, T-arrows represent the inhibition effect, and segments show the activation effect or inhibition effect.

![Fig. 8](image-url) Neuroprotective effects of SZJN prescription against glutamate-induced PC12 cell death. Cells were induced by glutamate solution (22.5 mM) and treated with SZJN prescription (0.05, 0.1 and 0.2 mg/mL) and MH (10 μM) containing the fluorescent dye YOYO-1 to identify dead cells for over 24 h using IncuCyte instrument (n = 3). Cells were imaged every 2 h for 24 h on the Essen Bio Science IncuCyte. a Time course cell viability analysis of PC12 cells using IncuCyte instrument. b-d Time course evaluation of total green fluorescent area, the number of dead cells and percent cell death over 24 h by YOYO-1 uptake on an IncuCyte instrument. e Representative images of YOYO-1 positive cells at 0, 12, 24, 36 hpt.
Fig. 8 (See legend on previous page.)
Fig. 9  SZJN prescription inhibited cell death through Apoptosis.  

a Cell apoptosis measured by Annexin V-FITC/PI staining.  

b Statistical columns of apoptotic cells.  

c Relative expression of caspase-3 mRNA in each group. The data were expressed as means ± SD (n = 3). *P<0.05, **P<0.01 showed significant difference compared with the control group (Control). #P<0.05, ##P<0.01 showed significant difference vs the glutamate-induced group (Glutamate)
kaempferol was revealed to improve the damage of striatal neurons and increase levels of tyrosine hydroxylase (TH) and postsynaptic density protein 95 (PSD95) in mice striata. This mechanism aided in anti-neuroinflammation and maintenance of the integrity of the blood-brain barrier (BBB) [41]. These findings demonstrate that the aforementioned compounds are associated with several important activities for VD treatment. Thus, they provide a basis for in-depth research on their active ingredients in SZJN prescription.

With regards to target points, PTGS2, PTGS1, PGR, ADRB2, ADRA1B, and CHRM1 recorded degrees ≥10. However, PTGS2 had a maximum degree of 17, an implication that it is a potential SZJN prescription target vital in the management of VD. PTGS2, also known as cyclooxygenase-2 (COX-2), is a subtype of prostaglandin G/H synthetase (PGHS), and a vital enzyme in fatty acid metabolism [42]. PTGS2 overexpression results in endothelial apoptosis, thus mediating vascular endothelial injury [43]. Downregulation of PTGS2 expression could inhibit apoptosis and promote proliferation, migration and angiogenesis of endothelial progenitor cells (EPCs) [44]. Similarly, PTGS1 (COX-1), another subtype of prostaglandin G/H synthetase, has been described as an important potential target for VD treatment. This enzyme protects gastrointestinal mucosa, promotes platelet aggregation, and induces peripheral vascular resistance through regulation of prostacyclin synthesis, closely associated with thrombosis [45–47]. PTGS1 has clear vascular protective roles associated with the anti-thrombotic potential, vasooconstriction and the development of atherosclerosis and vascular inflammation [48]. On the other hand, the steroid hormone PGR, potentially reduces oxidative stress and neuroinflammation, regulates mitochondrial function, and promotes myelination by triggering several signaling pathways, such as the MAPK and NF-κB signaling pathways. Therefore, it exerts a therapeutic effect on nervous system injury and neurodegenerative diseases [49]. ADRB2, a transmembrane β-adrenergic receptor, interacts with adrenaline (a hormone and neurotransmitter) to mediate muscle and nerve function through downstream interaction with L-type calcium channels [50]. Moreover, it has been demonstrated that activation of ADRB2 significantly increased EPCs bioactivities including cell proliferation, migration, and tube formation abilities [51]. However, downregulation of ADRB2 could induce the dysfunction of EPCs. There are reports on the critical role of CHRM1 in memory impairment, and a decrease in its density is associated with learning and memory disorder, and cognition dysfunction [52]. Researchers speculate that SZJN prescription may target the aforementioned proteins by regulating their expression levels to promote VD treatment. However, information on this relationship remains scarce and warrants further exploration.

The topology of the PPI network demonstrated that CASP3, JUN, ACHE, PPARG, PTGS2, ADRB2, CHRM1, ADRA1B, AR, PGR (degree ≥ 4.7) are potentially important targets for SZJN prescription in VD treatment. This is based on its multi-target, multi-path, and multi-system characteristics. However, all the targets in the network, except for PTGS2, were consistent with the PPI network. This controversy in results may be attributed to the scarcity of information regarding whether the herbs were processed or decocted, as well as the specificity of target action. It was found that CASP3 recorded the largest degree (8), therefore it acted as the main target for SZJN prescription. Caspase-3, a member of the cysteine protease family, is a downstream protein in the apoptosis pathway and an apoptotic enzyme that functions through the death receptor and mitochondrial pathways [53]. The apoptosis process may be attributed to the delayed neuronal degeneration of the central nervous system following injury to the distal axon [54]. Previous studies found a significant increase in Caspase-3 expression in the hippocampus of VD rats [55–58], which demonstrated that Caspase-3-mediated apoptosis may be an important molecular mechanism of VD [59, 60]. Herein, the treatment with SZJN prescription showed protective activity against glutamate-induced PC12 cell apoptosis. Similar reports have previously been published, whereby ginsenosides in SZJN prescription protected neural cells against glutamate-mediated oxidative stress and neuronal cell death [61, 62]. Moreover, a significant increase in the relative expression of Caspase-3 mRNA in PC12 cells was found after glutamate injury, consistent with reports from previous studies [63, 64]. This expression was, however, down-regulated with low, middle and high doses of SZJN prescription. Besides, MH significantly reduced the levels of Caspase-3 expression; this consequently inhibited cell apoptosis and protected the nerve cells. With these findings, SZJN prescription potentially lowers Caspase-3 expression and the apoptosis of neurons as it targets the Caspase-3. This is considered to be a vital step in the treatment of VD. Other targets, include JUN, a transcription factor for AP-1 that is closely linked to neuronal death caused by a β amyloid protein [65], this factor potentially activates the downstream apoptotic pathway.

In the present study, following GO functional enrichment analyses, it was revealed that target genes were...
associated with a drug reaction, transcription initiation of RNA polymerase II promoter, cell signal transduction, and cell proliferation, among others. These observations demonstrated that SZJN prescription may promote cell proliferation and reduce cell apoptosis. Results from related experiments indicate that SZJN prescription mediates the repair of damaged nerve cells via different mechanisms [66, 67].

Moreover, the KEGG metabolic pathway analysis revealed that the targets were associated with neuroactive ligand-receptor interaction, calcium, and cholinergic synapse signaling pathways. Of note, the neuroactive ligand-receptor interaction signaling pathway incorporates all receptors and ligands related to intracellular and extracellular signaling pathways in the plasma membrane. These include adrenergic, muscarinic acetylcholine receptor (mAChR), and dopamine receptors, among others [68]. Studies have attributed the abnormal expression of various receptor genes in the signaling pathway of receptor interaction in neuroactive ligands to a decline in learning and memory ability, and cognitive dysfunction [69–71]. Many subtypes of the adrenergic receptors, such as ADRB2, ADRA1A, ADRA1B, have been described, whereby a combination of these receptors and norepinephrine were found to regulate cell energy metabolism, glutamate transport, and neuroinflammatory response. These reports suggest that the adrenergic receptors represent a vital pharmacological target for the recovery and enhancement of cognitive function [72]. More studies have shown that muscarinic acetylcholine receptor (mAChR), an important neurodegenerative disease drug target, is linked to neuronal excitability, synaptic plasticity, acetylcholine release, and cognitive function, and possesses anti-apoptosis characteristics [73]. In this study, ADRB2, ADRA1A, ADRA1B, and CHRM1 were considered as SZJN prescription targets, and may exert a pharmacological effect in the management of VD through the interaction between ligands and receptors.

Due to the close relationship exists between the Ca^{2+} signaling pathway and signal transmission of neuron synapses, it was found that an open voltage-gated Ca^{2+} channel could activate NMDA receptors and drive the release of neurotransmitters. Also, an imbalance in the Ca^{2+} signaling pathway potentially activated apoptosis signaling molecules, such as Caspase-3 and Bax. This process inhibits the expression of Bcl-2 and consequently activates the apoptosis pathway [74]. Another report revealed significantly high calcium concentration in the primary hippocampal neurons following ischemia-reperfusion injury. This led to calcium overload, and subsequently activation of the apoptosis signaling pathway, which eventually induced neuron apoptosis [75]. In the present study, Caspase-3, Bax, and Bcl-2 were targets of SZJN prescription, therefore, had an association with the calcium signaling pathway. SZJN prescription exerted potential regulatory effects on the 3 targets via the calcium signaling pathway; this could be vital in the pharmacological treatment of VD.

Furthermore, the central cholinergic system coordinates synaptic plasticity, learning, and memory ability. Acetylcholine (ACh) is a neurotransmitter of the cholinergic pathway, and functions as a nicotinic (N) or muscarinic cholinergic receptor (CHRM1–5). Notably, excess hydrolysis of ACh by AChE has been implicated in the loss of cholinergic neurons, prolonged synaptic signal transmission disorder, and cognitive dysfunction [76]. Inhibition of AChE and activation of the cholinergic system have been reported to alleviate the central inflammatory response and repair the synaptic function [77]. This study reported AChE, CHRM1, and CHRM2 as targets for SZJN prescription, as they exerted potential effects via the cholinergic system. Therefore, it was hypothesized that SZJN prescription may regulate AChE, CHRM1, and CHRM2 via the cholinergic signaling pathway, which is critical in the pharmacological treatment of VD. Several other genes and metabolic pathways, as revealed by GO functional enrichment and KEGG metabolic pathways, may also be targets for active components of SZJN prescription. An in-depth analysis of these factors is needed to elucidate their potential molecular mechanisms in SZJN prescription.

However, there are still some limitations for this research. For example, the network pharmacology research relies more on various existing databases, but the screening criteria of compounds in databases may not be accurate enough. Moreover, the screened active ingredients might be inconsistent with the ingredients actually absorbed in blood of the patients with VD. As the accuracy and reliability of data has a great impact on the prediction results, it is necessary to further verify the reliability and quality of the predicted results, optimize the screening criteria of TCM databases, and improve the network pharmacology research. Therefore, further experimental and clinical verification of the efficacy of SZJN prescription on cerebrovascular microenvironment and neuroprotection is demanded to validate theoretical predictions.

**Conclusions**

In this study, a systematic analysis for the characteristic of “multicomponents, multitargets, and multichannels” of SZJN prescription in treating VD was successfully performed through the method of network pharmacology and in vitro experiments. The experimental results were in good accordance with the results predicted from the network analysis of the SZJN prescription,
especially the anti-apoptosis properties of the prescription. In the future, more experimental evidence should be provided for the neuroprotective and cerebral vascular protective effects of SZJN prescription against VD according to the results of network pharmacology research.

Abbreviations

ACHE: Acetylcholinesterase; AMPK: Adenosine 5'-monophosphate (AMP)-activated protein kinase; ADRA1A: Adrenergic receptor α1A; ADRA1B: Adrenergic receptor α1B; ADRB2: Adrenoceptor Beta 2; CASP3: Caspase-3; CHRM1: Muscarinic cholinergic receptor M1; CHRM2: Muscarinic cholinergic receptor M2; cAMP: Cyclic adenosine monophosphate; GO: Gene Ontology; JUN: Transcription factor AP-1; KEGG: Kyoto Enrichment of Genes and Genomes; NMDAR1: N-methyl-D-aspartic acid receptor 1; PPI network: Protein-Protein Interaction network; PTGS2: Prostaglandin-endoperoxide synthase 2; PTGS1: Prostaglandin-endoperoxide synthase 2; PGR: Progesterone receptor; PPARG: Peroxisome proliferator-activated receptor-gamma; qRT-PCR: Quantitative real-time polymerase chain reaction; VD: Vascular dementia.

Acknowledgments

We would like to extend our gratitude to Professor Zhen-Yun Han from the Shenzhen Hospital, Beijing University of Chinese Medicine (Longgang), Beijing, China, for providing valuable suggestions and revising the manuscript.

Authors’ contributions

DFT contributed to the experiments and writing original draft. QG contributed to software and data analysis. ZC and JFL contributed to methodology and experiment. ZYH contributed to the design and software. DYM contributed to supervision. ZYH contributed to the design of the work, funding acquisition, and revision. All authors have read and approved the final manuscript.

Funding

This study was supported by the National Natural Science Foundation of China with grant number 81673910. The funding body had no role in designing the study, collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that there is no conflict of interest regarding the publication of this paper.

Author details

1 Beijing University of Chinese Medicine, No.11 East road, North 3rd Ring Road, Beijing 100029, China. 2 Neurology Department of Dongzhimen Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Dongcheng District, Beijing 100700, China. 3 Shenzhen Hospital, Beijing University of Chinese Medicine (Longgang), No.1 Dayun road, Sports New City Road, Shenzhen 518172, China.

Received: 28 April 2020  Accepted: 17 November 2021

Published online: 02 February 2022

References

1. O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10049):1698–706.

2. Wolters FJ, Ikram MA. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542–9.

3. Singh V, Dhamoon MS, Alladi S. Stroke Risk and Vascular Dementia in South Asians. Curr Atheroscler Rep. 2018;20(9):43.

4. Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond). 2017;131(11):1059–68.

5. Pilon MH, Poulin S, Fortin MP, Houde M, Verret L, Bouchard RW, et al. Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer’s Disease and Vascular Dementia: a Retrospective Study. Neurology (E-Cronicon). 2016;26(2):278–86.

6. Chan ES, Bautista DT, Zhu Y, You Y, Long JT, Li W, et al. Traditional Chinese herbal medicine for vascular dementia. Cochrane Database Syst Rev. 2018;12(12):CD010284. https://doi.org/10.1002/14651858.CD010284.pub2 PMID: 30520514; PMCID: PMC6518669.

7. Guo S, Xu JJ, Wei N, Han JY, Xue R, Xu PS, et al. Honokiol attenuates the memory impairments, oxidative stress, Neuroinflammation, and GSK-3β activation in vascular dementia rats. J Alzheimers Dis. 2019;71(1):97–108. https://doi.org/10.3233/JAD-190324.

8. Zhao X, Liu J, Yang S, Song D, Wang C, Chen C, Li X, Wang Q, Ge S, Yang R, Liu X, Lin Y, Cai D. Long-Yang-Gou-Teng-decoction prevents vascular dementia through inhibiting oxidative stress induced neurovascular coupling dysfunction. J Ethnopharmacol. 2018;222:229–238. https://doi.org/10.1016/j.jep.2018.03.015. Epub 2018 Mar 13. PMID: 29542511.

9. Ma KK, Han ZY, Ma DY, Su R, Fan JP, Zhang FS. Effect of Shenzhi Jiaonao capsule on Glu and GABA in cortex and hippocampus of vascular dementia rat model (In Chinese). Liaoning J Trad Chin Med. 2016;43(11):2421–4.

10. Guo YY, Han ZY, Tian DF, Wang DH, Yu X, Guo J, et al. Protective effect and mechanism of ginseng-Anemarrhena-Paeoniae rubra extracts on hippocampal neurons in vascular dementia rats (In Chinese). Chin J Exp Pharmacol. 2019;25(08):47–53.

11. Lin H, Cui W, Sun SL, Zhang Z, Gao Y, Yan YF, et al. Protective effect of Shenzhi jiaonao formula on CA1 area of hippocampus in rats with vascular dementia (In Chinese). Chin J Basic Med Trad Chin Med. 2005;11(02):128–9+34.

12. Ma DY, Han ZY, Fan JP. Effect of shenzhijianao Capsule on central cholinergic system in mice with memory impairment induced by scopolamine (In Chinese). Chin J Trad Chin Med Inform. 2012;19(03):47–84+55.

13. Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol. 2011;5(Suppl 1):S10. https://doi.org/10.1186/1752-0509-5-S1-S10. PMID: 21689469; PMCID: PMC3121110.

14. Lyu M, Yan CL, Liu HK, Wang TY, Shi XH, Liu JP, et al. Network pharmacology exploration reveals endothelial inflammation as a common mechanism for stroke and coronary artery disease treatment of Danhong injection. Sci Rep. 2017;7(1):15427. https://doi.org/10.1038/s41598-017-14692-3. PMID: 29133791; PMCID: PMC5684234.

15. Steiger G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54(1):1.30. 1–30. 33.

16. Piñero J, Bravo A, Queralt-Rosinach N, Gutierrez-Sacristán A, Deu-Pons J, Centenero E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833–9. https://doi.org/10.1093/nar/gkw943. Epub 2016 Oct 19. PMID: 27924018; PMCID: PMC5210640.

17. Li PT, Wang YY, Huang QF. Formation and theoretical and practical significance of pathogenesis hypothesis of “toxic brain damage collaterals” (In Chinese). J Beijing Univ Tradit Chin Med. 2001;24(01):1–6+14.

18. Li L, Zhang L, Yang CC. Multi-target strategy and experimental studies of traditional Chinese medicine for Alzheimer’s disease therapy. Curr Top Med Chem. 2016;16(5):537–48.

19. Zeng Q, Li L, Liu W, Jin Y, Cao M, Li W, et al. A combined molecular biology and network pharmacology approach to investigate the multi-target mechanisms of Chaihu Shugan San on Alzheimer’s disease. Biomed Pharmacother. 2019;120:109370.

20. Cui L, Cai Y, Cheng W, Liu G, Zhao J, Cao H, et al. A novel, multi-target natural drug candidate, Matrine, improves cognitive deficits in Alzheimer’s disease. Front Pharmacol. 2020;11:352.
disease transgenic mice by inhibiting Aβ aggregation and blocking the RAGE/Aβ Axis. Mol Neurobiol. 2017;54(3):1939–52.
21. May BH, Feng M, Zhou IW, Chang SY, Lu SC, Zhang AL, et al. Memory Impairment, Dementia, and Alzheimer’s Disease in Classical and Contemporary Traditional Chinese Medicine. J Altern Complement Med. 2016;22(9):695–705.
22. Zheng M, Xin Y, Li Y, Xu F, Xi X, Guo H, et al. Ginsenosides: A Potential Neuroprotective Agent. Biomed Res Int. 2018;2018:8174345.
23. Xiao H, Li H, Song H, Kong L, Yan X, Li Y, et al. Shenzao jannao oral liquid, an herbal formula, ameliorates cognitive impairments by rescuing neuronal death and triggering endogenous neurogenesis in AD-like mice induced by a combination of Aβ42 and scopolamine. J Ethnopharmacol. 2020;259:112957. https://doi.org/10.1016/j.jep.2020.112957 Epub 2020 May 19. PMID: 32412648.
24. Dong D, Mao Y, Huang C, Jiao Q, Pan H, Ma L, et al. Astrocytes mediated the nootropic and neurotrophic effects of Sanasarapogenin-AA13 via upregulating brain-derived neurotrophic factor. Am J Transl Res. 2017;9(9):4015–25.
25. Zhao X, Liu C, Qi Y, Fang L, Luo J, Bi K, et al. Timosaponin B-II ameliorates scopolamine-induced cognition defects by attenuating acetylcholinesterase activity and brain oxidative damage in mice. Metab Brain Dis. 2016;31(6):1455–61.
26. Wang B, Dai W, Shi L, Teng H, Li X, Wang J, et al. Neuroprotection by Paeoniflorin against nuclear factor kappa B-activated NF-κB induced neuroinflammation on spinal cord injury. Biomed Res Int. 2018;2018:9865403.
27. Zheng M, Liu C, Fan Y, Shi D, Zhang Y. Protective effects of Paeoniflorin against MPP(+) induced neurotoxicity in PC12 cells. Neurochem Res. 2016;41(6):1325–34.
28. Ma DY, Cai ST, Zhang FS, Gao Q, Ma KX, Han ZY. Effect of single gastric perfusion of Shennzhi jannao capsule on the function of central nervous system in mice (In Chinese). Chin Med J. 2017;14(13):8–12.
29. Lee DG, Lee J, Kim KT, Lee SW, Kim YO, Cho IH, et al. High-performance liquid chromatography analysis of phytosterols in Panax ginseng root grown under different conditions. J Ginseng Res. 2018;42(1):16–20.
30. Lee HJ, Jeong J, Alves AC, Han ST, In G, Kim EH, et al. Metabolomic understanding of intrinsic physiology in Panax ginseng during whole growing seasons. J Ginseng Res. 2019;43(4):654–65.
31. Ji D, Huang ZY, Fei CH, Xue WW, Lu TL. Comprehensive profiling and characterization of chemical constituents of rhizome of Anemarrhena asphodeloides Bge. J Chromatogr B Anal Technol Biomed Life Sci. 2017;1060:355–66.
32. Parker S, May B, Zhang C, Zhang AL, Lu C, Xue CC. A pharmacological review of bioactive constituents of Panax notoginseng Pallas and Panax veitchii Lynch. Phytother Res. 2017;30(9):1445–73.
33. Liang Q, Yang J, He J, et al. Alpha-sitosterol enhances stigmasterol suppression tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor necrosis factor-α [J]. PLoS One. 2017;12(12):e0189626.
34. Adedeji OE, Olopade JO, Olayemi FO. Sodium metavanadate induced cognitive decline, behavioral impairments, oxidative stress and down regulation of myelin basic protein in mice hippocampus: ameliorative roles of β-sitosterol and stigmastanol. Brain Behav. 2018;8(7):e01014.
35. Lee JH, Parveen A, Do MH, et al. Lepsedzėcė cukrautė protects the endothelial dysfunction via eNOS phosphorylation of PI3K/Akt signaling pathway in HUVECs. Phymcthenec. 2018;48:1–9.
36. Zhang YL, Cheng X, Li WH, Liu M, Wang YH, Du GH. Kaempferol Attenuates LPS-Induced Striatum Injury in Mice Involving Anti-Neuroinflammation, Maintaining BBB Integrity, and Down-Regulating the HMGB1/TLR4 Pathway. Int J Mol Sci. 2019;20(3):491.
37. Astakhova A, Chistyakov D, Thomas D, Geislinger G, Brune B, Sergeeva M, et al. Inhibitors of Oxidative Phosphorylation Modulate Astrocyte Inflammatory Responses through AMPK-Dependent Pgs12 mRNA Stabilization. Cells. 2019;8(10):1185.
38. Qiu J, Wu Q, Cheng Q, et al. High glucose induces endothelial COX2 and iNOS expression via inhibition of monomethyltransferase SETD8 expression. J Diabetes Res. 2020;2020:2308520.
39. Zhou Z, Lu C, Meng S, et al. Silencing of PTGS2 exerts promoting effects on angiogenesis endothelial progenitor cells in mice with ischemic stroke via repression of the NF-κB signalling pathway. J Cell Physiol. 2019;234(12):23448–60.
40. Mitchell JA, Shala F, Elghazouli Y, Warner TD, Gason-Massuet C, Crescente M, et al. Cell-specific gene deletion reveals the antithrombotic function of COX1 and explains the vascular COX1/prostacyclin paradox. Circ Res. 2019;125(9):847–54.
41. Sakata C, Kawasaki T, Iwatsuki Y, Morita Y, Morita H. Inhibitory effects of ASP6537, a selective cyclooxygenase-1 inhibitor, on thrombosis and neointima formation in rats. Thromb Res. 2017;157:72–82.
42. Ma N, Yang GZ, Liu XW, Yang YJ, Mohamed M, Liu GR, et al. Impact of aspirin Eugenol Ester on Cyclooxygenase-1, Cyclooxygenase-2, C-reactive protein, Prothrombin and Arachidonate S-Lipoxigenase in healthy rats. Iran J Pharm Res. 2017;16(4):1443–51.
43. Mitchell JA, Shala F, Pires ME, et al. Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation. Sci Adv. 2021;7(12):eabf6504.
44. González SL, Coronel MF, Raggio MC, Laborbarda F. Progesteron receptor-mediated actions and the treatment of central nervous system disorders: an up-date of the known and the challenge of the unknown. Steroids. 2020;153:108525.
45. Han T, Shi YN, Zhang J, Bian Z, Fan Z-Y, Huang J, editors. System pharmacology-based approach to investigate the molecular targets of Bo-ai capsule for treating essential hypertension. 2019.
46. Lee SJ, Kim DY, Yun J, et al. Angiotensin II attenuates the bioactivities of human endothelial progenitor cells via Downregulation of B2-adrenergic receptor. Stem Cells Int. 2018;2018:743361.
47. Pala S, Atligan R, Kuluoglu T, Yalcin E, Kaya N, Etem E. The decrease in hippocampal transient receptor potential M2 (TRPM2) channel and muscarinic acetylcholine receptor 1 (CHRM1) is associated with memory loss in a surgical menopause rat model. Arch Med Sci. 2019;17(1):228-35.
48. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010;120(3):287–96.
49. Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H. Cortical neuronal apoptosis in CADASIL. Stroke. 2006;37(11):2690–5.
50. Zhang Y, Li Y, Wang Y, Wang G, Mao L, Zhang D, et al. Effects of resevoluter on learning and memory in rats with vascular dementia. Mol Med Rep. 2019;20(5):4587–93.
51. Huang K, Shen L, Niu T, Zhao Y, Fu J, Cao Y. Naomaitai ameliorated brain damage in rats with vascular dementia by P3iK/PDK1/ AKT signaling pathway. Evid Based Complement Alternat Med. 2019;2019:2702086.
52. Liao LX, Zhao MB, Dong X, Jiang Y, Zeng KW, Tu PF. TDB protects vascular endothelial cells against oxygen-glucose deprivation/reperfusion-induced injury by targeting mI-34a to increase Bcl-2 expression. Sci Rep. 2016;6:37959.
53. Li W, Yuan H, Yu Y, Cheong YK, Ren G, Yang Z. Etidronate rescues cognitive deficits through improving synaptic transmission and suppressing apoptosis in 2-vessel occlusion model rats. J Neurochem. 2017;140(5):476–84.
54. Zhang G, Liu A, Zhou Y, San X, Jin T, Jin Y. Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia. J Ethnopharmacol. 2008;115(3):441–8.
55. Borek C. Garlic reduces dementia and heart-disease risk. J Nutr. 2006;136(Suppl 8):1s–2s.
56. Liu Y, Wang S, Kan J, Zhang J, Zhou L, Huang Y, et al. Chinese herbal medicine interventions in neurological disorder therapeutics by regulating glutamate signaling. Curr Neuropharmacol. 2020;18(4):260–76.
62. Kim DH, Kim DW, Jung BH, Lee JH, Lee H, Hwang GS, et al. Ginsenoside Rb2 suppresses the glutamate-mediated oxidative stress and neuronal cell death in HT22 cells. J Ginseng Res. 2019;43(2):326–34.

63. Smidkova I, Hajek M, Adla SK, Slavikova B, Chodounska H, Matousova M, et al. Screening of novel 3α5β-neurosteroids for neuroprotective activity against glutamate- or NMDA-induced excitotoxicity. J Steroid Biochem Mol Biol. 2019;189:195–203.

64. Akanda MR, Kim MJ, Kim S, Ahn D, Tae HJ, Rahman MM, et al. Neuroprotective effects of Sigsbeckia pubescens extract on glutamate-induced oxidative stress in HT22 cells via Downregulation of MAPK/caspase-3 pathways. Cell Mol Neurobiol. 2018;38(2):497–505.

65. Akhter R, Sanphui P, Das H, Saha P, Biswas SC. The regulation of p53 up-regulated modulator of apoptosis by JNK/c-Jun pathway in β-amyloid-induced neuron death. J Neurochem. 2015;134(6):1091–103.

66. Niu MY, He X, Hu JH, Zhang SJ, Gao YS, Wu Q, et al. Study on the neuroprotective mechanism of Shenzhi Jiannao formula on hypoxia SH-SY5Y cells. (In Chinese). J Hupei Univ Tradit Chin Med. 2016;18(03):1–4.

67. Wu Q, Zhang SJ, Zhang YC, Xing ENL, Yang AOR, Hu JH, et al. Study on the protective mechanism of Shenzhi Jiannao formula on brain mitochondrial damage in rats with cognitive impairment caused by hypoxia. (In Chinese). World Tradit Chin Med. 2017;12(10):2403–7.

68. Su SY, Hsieh CL, Wu SL, Cheng WY, Li CC, Lo HY, et al. Transcriptomic analysis of EGB 761-regulated neuroactive receptor pathway in vivo. J Ethnopharmacol. 2009;123(1):68–73.

69. Maurice T, Goguadze N. Role of α(1) receptors in learning and memory and Alzheimer’s disease-type dementia. Adv Exp Med Biol. 2017;964:213–33.

70. Miller KK. Neuroactive Steroids and Depression. In: Benjamin G, Shapero DM, Cusin C, editors. The Massachusetts General Hospital Guide to Depression. Current Clinical Psychiatry. Cham: Humana Press; 2019. p. 147–51.

71. Tuem KB, Atey TM. Neuroactive steroids: receptor interactions and responses. Front Neurol. 2017;8:442.

72. Hertz L, Chen Y. Chapter 2 - Astroglial adrenergic receptor signaling in brain cortex. In: Vardjan N, Zorec R, editors. Noradrenergic Signaling and Astroglia. United States of America: Academic Press, 2017. p. 25–61.

73. Chee LY, Cumming A. Polymorphisms in the cholinergic receptors muscarinic (CHRM2 and CHRM3) genes and Alzheimer’s disease. Avicenna J Med Biotechnol. 2018;10(3):196–9.

74. He W, Sun JF, Jiang RY, Zhang ZJ, Chen Q, Huang YH. Effect of calcium-sensing receptor on the apoptosis of rat spinal cord neurons in anoxia/reoxygenation injury and its significance. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2017;39(5):623–8.

75. Magi S, Castaldo P, Macrì ML, Maiolino M, Matteucci A, Bastioli G, et al. Intracellular calcium Dysregulation: implications for Alzheimer’s disease. Biomed Res Int. 2016;2016:6071324.

76. Ferreira-Vieira TH, Guimarães IF, Silva FR, Ribeiro FM. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):10–15.

77. Lee J, Kwon H, Yu J, Cho E, Jeon J, Lee S, et al. The enhancing effect of Aubang Gahl Soo on the hippocampal synaptic plasticity and memory through enhancing cholinergic system in mice. J Ethnopharmacol. 2018;224:91–9. https://doi.org/10.1016/j.ejp.2018.05.017 Epub 2018 May 26. PMID: 29842961.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.